These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection. Jang YH; Seong BL Expert Opin Drug Discov; 2020 Dec; 15(12):1441-1455. PubMed ID: 32783765 [TBL] [Abstract][Full Text] [Related]
4. Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines. Wang P; Zheng M; Lau SY; Chen P; Mok BW; Liu S; Liu H; Huang X; Cremin CJ; Song W; Chen Y; Wong YC; Huang H; To KK; Chen Z; Xia N; Yuen KY; Chen H mBio; 2019 Sep; 10(5):. PubMed ID: 31530680 [TBL] [Abstract][Full Text] [Related]
5. The Quest for a Truly Universal Influenza Vaccine. Jang YH; Seong BL Front Cell Infect Microbiol; 2019; 9():344. PubMed ID: 31649895 [TBL] [Abstract][Full Text] [Related]
6. Pan-Influenza A Protection by Prime-Boost Vaccination with Cold-Adapted Live-Attenuated Influenza Vaccine in a Mouse Model. Jang YH; Kim JY; Byun YH; Son A; Lee JY; Lee YJ; Chang J; Seong BL Front Immunol; 2018; 9():116. PubMed ID: 29449842 [TBL] [Abstract][Full Text] [Related]
7. Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine. Wan Z; Cardenas Garcia S; Liu J; Santos J; Carnaccini S; Geiger G; Ferreri L; Rajao D; Perez DR J Virol; 2018 Nov; 92(21):. PubMed ID: 30135124 [TBL] [Abstract][Full Text] [Related]
8. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses. Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P J Virol; 2017 May; 91(9):. PubMed ID: 28179535 [TBL] [Abstract][Full Text] [Related]
9. Development of an Alternative Modified Live Influenza B Virus Vaccine. Santos JJS; Finch C; Sutton T; Obadan A; Aguirre I; Wan Z; Lopez D; Geiger G; Gonzalez-Reiche AS; Ferreri L; Perez DR J Virol; 2017 Jun; 91(12):. PubMed ID: 28381580 [TBL] [Abstract][Full Text] [Related]
10. Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model. Liu WC; Nachbagauer R; Stadlbauer D; Solórzano A; Berlanda-Scorza F; García-Sastre A; Palese P; Krammer F; Albrecht RA Front Immunol; 2019; 10():756. PubMed ID: 31105689 [TBL] [Abstract][Full Text] [Related]
11. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge. Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689 [TBL] [Abstract][Full Text] [Related]
18. Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture. Rajão DS; Pérez DR Front Microbiol; 2018; 9():123. PubMed ID: 29467737 [TBL] [Abstract][Full Text] [Related]
19. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses. Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203 [TBL] [Abstract][Full Text] [Related]